Susceptibility of Candida dubliniensis to salivary histatin 3

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 70-76

  Fitzgerald, Deirdre H ^a   Coleman, David C ^a   O'Connell, Brian C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; HISTATIN; HISTATIN 3; HISTIDINE; ITRACONAZOLE; KETOCONAZOLE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG MECHANISM; FUNGUS ISOLATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND; THRUSH;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDA; CANDIDIASIS, ORAL; HUMANS; PROTEINS;

EID: 12244309107     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.70-76.2003     Document Type: Article

References (39)

1. Beck-Sague, C. M., W. R. Jarwis, et al. 1993. Secular trends in the epidemiology of nosocomial fungal infection in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251.
2. Bercier, J. G., I. Al-Hashimi, N. Haghighat, T. D. Rees, and F. G. Oppenheim. 1999. Salivary histatins in patients with recurrent oral candidiasis J. Oral Pathol. Med. 28:26-29.
3. Boyle, B. M., D. J. Sullivan, C. Forkin, F. Mulcahy, C. T., Keane, and D. C. Coleman. 2002. Candida dubliniensis candidaemia in an HIV-positive patient in Ireland. Int. J. STD AIDS 13:55-57.
4. Brandt, M. E., L. H. Harrison, M. Pass, A. N. Sofair, S. Huie, R. K. Li, C. J. Morrison, D. W. Warnock, and R. A. Hajjeh. 2000. Candida dubliniensis fungemia: the first four cases in North America. Emerg. Infect. Dis. 6:46-49.
5. Calderone, R. A., and W. A. Fonzi. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9:327-335.
6. Coleman, D., D. Sullivan, B. Harrington, K. Haynes, M. Henman, D. Shanley, D. Bennett, G. Moran, C. McCreary, L O'Neill. 1997. Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis. 3(Suppl. 1):S96-101.
7. Edgerton, M., S. E Koshlukova, T. E. Lo, B. G. Chrzan, R. M. Straubinger, and P. A. Raj. 1998. Candidacidal activity of salivary histatins. Identification of a histatin 5 binding protein on Candida albicans. J. Biol. Chem. 273:20438-20447.
8. Fung-Tomc, J. C., T. C. White, B. Minassian, E. Huczko, and D. P. Bonner. 1999. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. 35:163-167.
9. Gallagher, P. J., D. E. Bennett, M. C. Henman, R. J. Russell, S. R. Flint, D. B. Shanley, and D. C. Coleman. 1992. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J. Gen. Microbiol. 138:1901-1911.
10. Gee, S., S. Joly, D. R. Soll., J. F. G. M. Meis, P. E. Verweij, I. Polacheck, D. J. Sullivan, and D. C. Coleman. 2002. Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J. Clin. Microbiol. 40:556-574.
11. Helmerhorst, E. J., P. Breeuwer, W. van't Hof, E. Walgreen-Weterings, L. C. Oomen, E. C. Veerman, A. V. Amerongen, and T. Abee. 1999. The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J. Biol. Chem. 274:7286-7291.
12. Helmerhorst, E. J., I. M. Reijnders, W. van't Hof, I. Simoons-Smit, E. C. Veerman, and A. V. Amerongen. 1999. Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob. Agents Chemother. 43:702-704.
13. Jainkittivong, A., D. A. Johnson and C-K. Yeh. 1998. The relationship between salivary histatin levels and oral yeast carriage. Oral Microbiol. Immunol. 13:181-187.
14. Kirkpatrick, W. R., S. G. Reyankar, R. K. Mcatee, J. L. Lopez-Ribot, A. W. Fothergill, D. I. McCarthy, S. E. Sanche, R. A. Cantu, M. G. Rinaldi, and T. F. Patterson. 1998. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar CANDIDA screening and susceptibility testing of isolates. J. Clin. Microbiol. 36:3007-3012.
15. Koshlukova, S. E., M. W. B. Araujo, D. Baev, and M. Edgerton. 2000. Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans. Infect. Immun. 68:6848-6856.
16. Lal, K., J. J. Pollock, R. P. Santarpia III, H. M. Heller, H. W. Kaufman, J. Fuhrer, and R. T. Steigbigel. 1992. Pilot study comparing the salivary cationic protein concentrations in healthy adults and AIDS patients: correlation with antifungal activity. J. Acquir. Immune Defic. Syndr. 5:904-914.
17. Löffler, J., S. L. Kelly, H. Hebart, U. Schumacher C. Lass-Florl, and H. Einsele. 1997. Molecular analysis of cyp5l from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
18. MacKay, D. J., L. Denepitiya, V. J. Iacono, S. B. Krost, and J. J. Pollock. 1984. Growth inhibitory and bacteriocidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect. Immun. 44:695-701.
19. Meis, J. F., M. Ruhnke, B. E. De Pauw, F. C. Odds, W. Siegert, and P. E. Verweij. 1999. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg. Infect. Dis. 5:150-153.
20. Moran, G. P., D. Sanglard, S. M. Donnelly, D. B. Shanley, D. J. Sullivan, and D. C. Coleman. 1998. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42:1819-1830.
21. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41:617-623.
22. Murakami, Y., H. Nagata, A. Amano, M. Takagaki, S. Shizukuishi, A. Tsunemitsu, and S. Aimoto. 1991. Inhibitory effects of human salivary histatins and lysozyme on coaggregation between Porphyromonas gingivalis and Streptococcus mitis. Infect. Immun. 59:3284-3286.
23. Nikawa, H., C. Jin, H. Fukushima, S. Makihira, and T. Hamada. 2001. Antifungal activity of histatin-5 against non-albicans Candida species. Oral Microbiol. Immunol. 16:250-252.
24. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 4:196-199.
25. Pfaller, M. A., S. A. Messer, S. Dee, S. Joly, C. Pujol, D. J. Sullivan, D. C. Coleman, and D. R. Soll. 1999. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37:870-872.
26. Pinjon, E., D. J. Sullivan, L. Salkin, D. B. Shanley, and D. C. Coleman. 1998. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J. Clin. Microbiol. 36:2093-2095.
27. Polacheck, I. J. Strahilevitz, D. Sullivan, S. Donnelly, I. F. Salkin, and D. C. Coleman. 2000. Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel. J. Clin. Microbiol. 38:170-174.
28. Pollock, J. J., L. Denepitiya, B. J. MacKay, and V. J. Iacono. 1984. Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect. Immun. 45:610-617.
29. Rayhan, R., L. Xu, R. P. Santarpia III, C. A Tylenda, and J. J. Pollock. 1992. Antifungal activities of salivary histidine-rich polypeptides against Candida albicans and other oral yeast isolates. Oral Microbiol. Immunol. 7:51-52.
30. Rocco, T. R. S. E. Reinert, and H. H. Simms. 2000. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch. Surg. 135:160-165.
31. Rothstein, D. M. P. Spacciapoli, L. T. Tran, T. Xu, F. D. Roherts, M. Dalla Serra, D. K. Buxton, F. G. Oppenheim, and P. Friden. 2001. Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrob Agents Chemother. 45:1367-1373.
32. Salesa, R., M. D. Moragues, R. Sota, J. Peman, G. Quindos, and J. Ponton. 2001. Specific antibody response in a patient with Candida dubliniensis fungemia. Rev. Iberoam. Micol. 18:42-44.
33. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405-416.
34. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
35. Situ, H., and L. A. Bobek. 2000. In vitro assessment of antifungal therapeutic potential of salivary histatin 5, two variants of histatin 5 and salivary mucin (MUC7) Domain 1. Antimicrob. Agents Chemother. 44:1485-1493.
36. Sullivan, D. J., T. J. Westerneng, K. A. Haynes, D. E. Bennett, and D. C. Coleman. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology. 41:1507-1521.
37. Tsai. H., and L. A. Bobek. 1997. Studies of the mechanism of human salivary histatin 5 candidacidal activity with histatin 5 variants and azole-sensitive and -resistant Candida species. Antimicrob. Agents Chemother. 41:2224-2228.
38. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
39. Xu, Y., I. Ambudkar, H. Yamagishi, W. Swaim, T. J. Walsh, and B. C. O'Connell. 1999. Histatin 3-mediated killing of Candida albicans: effects of extracellular salt concentration on binding and internalization. Antimicrob. Agents Chemother. 43:2256-2262.